Synergistic insecticidal compositions
11 claims: 11 independent, 0 dependent
- 1An insecticidal composition comprising a neuronal sodium channel antagonist of formula I:wherein A is CR4R5 or NR6;W ist O or S;X, Y and Z are each independently H;halogen;OH;CN;NO2;C1-C6-alkyl unsubstituted or substituted with one or more halogen, C1-C3-alkoxy, C1-C3-haloalkoxy, C3-C6-cycloalkyl,C2-C6-alkenyloxy or sulfonyloxy groups;C1-C6-alkoxy unsubstituted or substituted with one or more halogen C1-C3-alkoxy or C3-C6-cycloalkyl groups;C1-C6-alkoxycarbonyl, C3-C6-cycloalkylcarbonyloxy, phenyl unsubstituted or substituted with one or more halogen, C1-C4-alkyl or C1-C4-alkoxy groups;aminocarbonyloxy unsubstituted or substituted with one or more C1-C3-alkyl groups;C1-C6-alkoxycarbonyloxy;C1-C6-alkylsulfonyloxy;C2-C6-alkenyl;or NR7R8;m, p and q are each independently an integer of 1, 2, 3, 4 or 5;n is an integer of 0, 1 or 2;R, R1, R2, R3, R4 and R5 are each independently H or C1-C4-alkyl;R6 is H, C1-C6-alkyl, C1-C6-haloalkyl, C1-C6-alkoxyalkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, C2-C6-alkenyl, C2-C6-alkynyl , C1-C6-alkylcarbonyl, C1-C6-alkoxycarbonyl, C1-C6-alkylthio, or C1-C6-haloalkylthio;R7 and R8 are each independently H or C1-C6-alkyl;and the dotted line configuration represents a double bond or a single bond;or a stereoisomer thereof, and one or more compounds selected from Group A: 1) pyrethroid compounds;2) pyrethroid-type compounds;3) recombinant nucleopolyhedroviruses capable of expressing an insect neurotoxin;4) organophosphate compounds;5) carbamate compounds;6) formamidine compounds;7) macrocyclic lactone compounds;8) amidinohydrazone compounds;9) GABA antagonist compounds;10) acetylcholine receptor ligand compounds11) in synergistically active amounts. Composition insecticide comprenant un antagoniste de canal sodique neuronal de formule I : dans laquelle A représente CR4R5 ou NR6,W représente O ou S,X, Y et Z représentent chacun indépendamment H, de l'halogène, OH, CN, NO2, un radical alkyle en C1-C6 non substitué ou substitué par un ou plusieurs halogènes, des groupes alcoxy en C1-C3, halogénoalcoxy en C1-C3, cycloalkyle en C3-C6, alcényloxy en C2-C6 ou sulfonyloxy, un radical alcoxy en C1-C6 non substitué ou substitué par un ou plusieurs halogènes, des groupes alcoxy en C1-C3 ou cycloalkyle en C3-C6, un radical alcoxycarbonyle en C1-C6, cycloalkylcarbonyloxy en C3-C6, phényle non substitué ou susbtitué par un ou plusieurs halogènes, groupes alkyle en C1-C4 ou alcoxy en C1-C4, un radical aminocarbonyloxy non substitué ou substitué par un ou plusieurs groupes alkyle en C1-C3, un radical alcoxycarbonyloxy en C1-C6, alkylsulfonyloxy en C1-C6, alcényle en C2-C6, ou NR7R8,m, p et q sont chacun indépendamment un nombre entier parmi 1, 2, 3, 4 ou 5,n est un nombre entier parmi 0, 1 ou 2,R,R1, R2, R3, R4 et R5 représentent chacun indépendamment H ou un groupe alkyle en C1-C4,R6 représente H, un groupe alkyle en C1-C6, halogénoalkyle en C1-C6, alcoxyalkyle en C1-C6, alcoxy en C1-C6, halogénoalcoxy en C1-C6, alcényle en C2-C6, alcynyle en C2-C6, alkylcarbonyle en C1-C6, alcoxycarbonyle en C1-C6, alkylthio en C1-C6, ou halogénoalkylthio en C1-C6,R7 et R8 représentent chacun indépendamment H ou un groupe alkyle en C1-C6, et la configuration à ligne pointillée représente une double liaison ou une simple liaison, ou un stéréoisomère de celui-ci, et un ou plusieurs composés choisis parmi le groupe A : 1) composés de pyréthroïde,2) composés de type pyréthroïde,3) nucléopolyhédrovirus recombinants, capables d'exprimer une neurotoxine d'insecte,4) composés d'organophosphate,5) Composés de carbamate,6) Composés de formamidine,7) composés de lactone macrocyclique,8) composés d'amidinohydrazone,9) composés antagonistes de GABA,10) composés de ligand récepteur d'acétylcholine,11) en des quantités actives du point de vue synergique. Insektizide Zusammenfassung, die einen Neuronen-Natriumkanalantagonisten der Formel I in der A CR4R5 oder NR6 bedeutet;W O oder S bedeutet;X, Y und Z jeweils unabhängig H;Halogen;OH;CN;NO2;C1-C6-Alkyl, das unsubstituiert oder durch eine oder mehrere Halogen-, C1-C3-Alkoxy-, C1-C3-Halogenalkoxy-, C3-C6-Cycloalkyl-, C2-C6-Alkenyloxy- oder Sulfonyloxygruppen substituiert ist;C1-C6-Alkoxy, das unsubstituiert oder durch eine oder mehrere Halogen-, C1-C3-Alkoxy- oder C3-C6-Cycloalkylgruppen substituiert ist;C1-C6-Alkoxycarbonyl , C3-C6-Cycloalkylcarbonyloxy, Phenyl, die unsubstituiert oder durch eine oder mehrere Halogen-, C1-C4-Alkyl- oder C1-C4-Alkoxygruppen substituiert sind;Aminocarbonyloxy, das unsubstituiert oder durch eine oder mehrere C1-C3-Alkylgruppen substituiert ist;C1-C6-Alkoxycarbonyloxy;C1-C6-Alkylsulfonyloxy, C2-C6-Alkenyl;oder NR7R8 bedeuten;m, p und q jeweils unabhängig eine ganze Zahl 1, 2, 3, 4 oder 5 bedeuten;n eine ganze Zahl 0, 1 oder 2 bedeutet;R, R1, R2, R3 , R4 und R5 jeweils unabhängig H oder C1-C4-Alkyl bedeuten;R6 H, C1-C6-Alkyl, C1-C6-Halogenalkyl, C1-C6-Alkoxyalkyl, C1-C6- Alkoxy, C1-C6-Halogenalkoxy, C2-C6-Alkenyl , C2-C6-Alkinyl, C1-C6-Alkylcarbonyl , C1-C6-Alkoxycarbonyl, C1-C6-Alkylthio oder C1-C6-Halogenalkylthio bedeutet;R7 und R8 jeweils unabhängig H oder C1-C6-Alkyl bedeuten;und die Konfiguration mit der gebrochenen Linie eine Doppelbindung oder Einfachbindung bedeutet;oder ein Stereoisomer davon;sowie eine oder mehrere Verbindungen aus der Gruppe A: 1) Pyrethroidverbindungen;2) pyrethroidartige Verbindungen;3) rekombinante Kernpolyederviren, die ein Insektenneurotoxin exprimieren können;4) phosphororganische Verbindungen;5) Carbamatverbindungen;6) Formamidinverbindungen;7) Makrolidverbindungen;8) Amidinhydrazonverbindungen;9) GABA-Antagonisten-Verbindungen;10) Acetylcholinrezeptorliganden-Verbindungen;in synergistischen Mengen umfaßt.
- 2Composition suivant la revendication 1, dans laquelle, dans la formule I, W est O, X est du 4-trifluorométhoxy, Y est du 3-trifluorométhyle, Z est du 4-CN, A est du CH2, n vaut 0, m, p et q valent chacun 1, R et R1 sont chacun H, et la configuration à ligne pointillée représente une double liaison. The composition according to claim 1 wherein in formula I, W is O;X is 4-trifluoromethoxy;Y is 3-trifluoromethyl;Z is 4-CN;A is CH2;n is O;m, p and q are each 1;R and R1 are each H;and the dotted line configuration represents a double bond. Zusammensetzung nach Anspruch 1, wobei in Formel I W O bedeutet;X 4-Trifluormethoxy bedeutet;Y 3-Trifluormethyl bedeutet;Z 4-CN bedeutet;A CH2 bedeutet;n 0 bedeutet;m, p und q jeweils 1 bedeuten;R und R1 jeweils H bedeuten;und die Konfiguration mit der gebrochenen Linie eine Doppelbindung bedeutet.
- 3Composition suivant la revendication 2, dans laquelle les un ou plusieurs composés choisis parmi le groupe A sont du cyperméthrin, du cyhalométhrin, du cyfluthrin, du perméthrin, de l'éthofenprox, du silafluofen, du fipronil, de l'endosulfone, de l'imidacloprid, de l'acétamiprid, du nitenpyram, du thiaméthoxam, du profénofos, de l'acéphate, du sulprofos, du malathion, du diazinon, du méthyl parathion, du terbufos, du méthonyl, du thiodicarb, du fénothiocarb, de l'amitraz, du chlordiméform, de la chlorfénamidine, de l'avermectin, de l'émamectin, du milbémectin, du némadectin ou du moxidectin. The composition according to claim 2 wherein the one or more compounds selected from Group A are cypermethrin, cyhalomethrin, cyfluthrin, permethrin, ethofenprox, silafluofen, fipronil, endosulfon, imidacloprid, acetamiprid, nitenpyram, thiamethoxam, profenofos, acephate, sulprofos, malathion, diazinon, methyl parathion, terbufos, methonyl, thiodicarb, fenothiocarb, amitraz, chlordimeform, chlorfenamidine, avermectin, emamectin, milbemectin, nemadectin or moxidectin. Zusammensetzung nach Anspruch 2, wobei es sich bei der einen bzw. bei den mehreren Verbindungen aus der Gruppe A um Cypermethrin, Cyhalomethrin, Cyfluthrin, Permethrin, Ethofenprox, Silafluofen, Fipronil, Endosulfon, Imidacloprid, Acetamiprid, Nitenpyram, Thiamethoxam, Profenofos, Acephate, Sulprofos, Malathion, Diazinon, Methylparathion, Terbufos, Methonyl, Thiodicarb, Fenothiocarb, Amitraz, Chlordimeform, Chlorfenamidin, Avermectin, Emamectin, Milbemectin, Nemadectin oder Moxidectin.
- 4Composition suivant la revendication 2, dans laquelle les un ou plusieurs composés choisis parmi le groupe A sont de l'hydraméthylnone. The composition according to claim 2 wherein the one or more compounds selected from Group A is hydramethylnon. Zusammensetzung nach Anspruch 2, wobei es sich bei der einen bzw. den mehreren Verbindungen aus der Gruppe A um Hydramethylnon handelt.
- 5A bait composition containing by weight 0,01 % to 20 % of a neuronal sodium channel antagonist of formula I as defined in claim 1 in combination with hydramethylnon. Composition d'attraction contenant 0,01 % à 20 % en poids d'un antagoniste de canal sodique neuronal de la formule I, tel que défini dans la revendication 1, en combinaison avec de l'hydra-méthylnone. Köderzusammensetzung, die 0,01 Gew.-% bis 20 Gew.-% eines Neuronen-Natriumkanalantagonisten der Formel I nach Anspruch 1 in Kombination mit Hydramethylnon enthält.
- 6Composition suivant les revendications 1 à 4, dans laquelle le rapport entre les composants actifs est de 1 partie en poids d'antagoniste de canal sodique neuronal de formule I, comme défini dans la revendication 1, pour 0,01 à 100 parties en poids d'un ou plusieurs composés du groupe A, tel que défini dans la revendication 1. The composition according to claims 1 to 4 wherein the ratio of the active ingredients is 1 weight part of a neuronal sodium channel antagonist of formula I as defined in claim 1 to 0,01 to 100 weight parts of one or more compounds of group A as defined in claim 1. Zusammensetzung nach den Ansprüchen 1 bis 4, wobei das Verhältnis der Wirkstoffe 1 Gewichtsteil eines Neuronen-Natriumkanalantagonisten der Formel I nach Anspruch 1 zu 0,01 bis 100 Gewichtsteilen von einer oder mehreren Verbindung(en) der in Anspruch 1 definierten Gruppe A beträgt.
- 7A method for insect control which comprises contacting said insect with a composition according to claims 1 to 4. Procédé de contrôle des insectes qui comprend une mise en contact dudit insecte avec une composition suivant les revendications 1 à 4. Verfahren zur Bekämpfung von Insekten, dadurch gekennzeichnet, daß man das Insekt mit einer Zusammensetzung nach den Ansprüchen 1 bis 4 in Kontakt bringt.
- 8A method for protecting a plant from infestation and attack by insects which comprises applying to the foliage or stem of said plant a synergistically effective amount of a composition according to claims 1 to 4. Procédé de protection d'une plante vis-à-vis d'une infestation et d'une attaque par des insectes, qui comprend une application sur le feuillage ou la tige de ladite plante d'une quantité efficace du point de vue synergique d'une composition suivant les revendications 1 à 4. Verfahren zum Schützen einer Pflanze gegen Befall mit bzw. Angriff von Insekten, dadurch gekennzeichnet, daß man eine synergistisch wirksame Menge einer Zusammensetzung nach den Ansprüchen 1 bis 4 auf das Blattwerk oder den Stängel der Pflanze ausbringt.
- 9Use of compositions according to claims 1 to 6 for combating insects of the orders Lepidoptera and Coleoptera. Utilisation de compositions suivant les revendications 1 à 6, pour combattre des insectes des ordres des lépidoptères et des coléoptères. Verwendung von Zusammensetzungen nach den Ansprüchen 1 bis 6 zur Bekämpfung von Insekten der Ordnungen Lepidoptera und Coleoptera.
- 10Use of compositions according to claims 1 to 6 for the control of hygienic or public health pests selected from the group Diptera, Hymenoptera and Blattaria. Utilisation de compositions suivant les revendications 1 à 6, pour le contrôle d'insectes nuisibles à l'hygiène ou la santé publique choisis parmi le groupe des diptères, des hyménoptères et des Blattaria. Verwendung von Zusammensetzungen nach den Ansprüchen 1 bis 6 für die Kontrolle von Hygieneschädlingen oder Volksgesundheitsschädlingen aus der Gruppe Diptera, Hymenoptera und Blattaria.
- 11Use of compositions according to claims 1 to 6 for the control of wood-eating insects selected from the group Hymenoptera, Isoptera and Coleoptera. Utilisation de compositions suivant les revendications 1 à 6 pour le contrôle des insectes xylophages choisis parmi le groupe des hyménoptères, des isoptères et des coléoptères. Verwendung von Zusammensetzungen nach den Ansprüchen 1 bis 6 für die Kontrolle von holzverzehrenden Insekten aus der Gruppe Hymenoptera, Isoptera und Coleoptera.
Independent claims11
43 paragraphs in 6 sections, as filed
BACKGROUND OF THE INVENTION
Insecticidal agents and compositions have been developed to control insect pests such as agrohorticultural pests, hygienic pests, or wood-eating pests and in practice have been used as a single or a mixed agent. However, economically efficient and ecologically safe insect control compositions are still being sought. Insecticidal compositions which allow for reduced effective dosage rates, increased environmental safety and lower incidence of insect resistance are highly desirable. Although the rotational application of insect control agents having different modes of action may be adopted for good pest management practice, this approach does not necessarily give satisfactory insect control. Further, even though combinations of insect control agents have been studied, a high synergistic action has not always been found. Obtaining an insecticidal composition which demonstrates no cross-resistance to existing insecticidal agents, no toxicity problems and little negative impact on the environment is extremely difficult.
Therefore, it is an object of this invention to provide a synergistic insecticidal composition which demonstrates a high controlling effect with concomittant reduced crop production cost and reduced environmental load.
It is another object of this invention to provide methods for synergistic insect control and enhanced crop protection.
SUMMARY OF THE INVENTION
The present invention provides an insecticidal composition comprising as essential active ingredients a neuronal sodium channel antagonist of formula I in combination with one or more compounds selected from the group consisting of pyrethroids, pyrethroid-type compounds, recombinant nucleopolyhedroviruses capable of expressing an insect toxin, organophosphates, carbamates, formamidines, macrocyclic lactones, amidinohydrazones, GABA (gamma-aminobutyric acid) antagonists, and acetylcholine receptor ligands in synergistically active amounts.
The present invention also provides a method for insect control which comprises contacting said insect with a synergistically effective amount of a neuronal sodium channel antagonist in combination with one or more compounds selected from the group consisting of pyrethroids, pyrethroid-type compounds, recombinant nucleopolyhedroviruses capable of expressing an insect toxin, organophosphates, carbamates, formamidines, macrocyclic lactones, amidinohydrazones, GABA antagonists and acetylcholine receptor ligands.
The present invention further provides a method for the enhanced protection of plants from infestation and attack by insects.
DETAILED DESCRIPTION OF THE INVENTION
Definitions
"Acetylcholine receptor ligand compound" as used in this application means a compound which is capable of binding to the acetylcholine receptor site.
"Group A" as used in this application means insecticidal <ul id="ul0001" list-style="none" compact="compact"><li>1) pyrethroid compounds;</li><li>2) pyrethroid-type compounds;</li><li>3) recombinant nucleopolyhedroviruses capable of expressing an insect toxin;</li><li>4) organophosphate compounds;</li><li>5) carbamate compounds;</li><li>6) formamidine compounds;</li><li>7) macrocyclic lactone compounds;</li><li>8) amidinohydrazone compounds;</li><li>9) GABA antagonist compounds; and</li><li>10) acetylcholine receptor ligand compounds.</li></ul>
"Haloalkyl" as used in this application means an alkyl group C<sub>x</sub>H<sub>2x+1</sub>, having 1 to 2x+1 halogen atoms which may be the same or different. Similarly, the terms "haloalkenyl", "haloalkynyl", "haloalkoxy", "halophenyl" and the like mean mono- to perhalogen substitution wherein the halogens may be the same or different.
"Halogen" as used in this application means Cl, Br, I or F.
"Neuronal sodium channel antagonist" as used in this application means a compound which is capable of preventing the ability of a neuron cell to transfer sodium ions across the cell membrane. "Pyrethroid-type compounds" as used in this application means those compounds characterized by a non-ester linked aryl-phenoxybenzyl moiety. "Synergism" as used in this application means a cooperative action encountered in a combination of two or more bioiogically active components in which the combined activity of the two or more components exceeds the sum of the activity of each component alone.
Surprisingly, it has now been found that a composition which comprises a combination of a neuronal sodium channel antagonist and a second insecticidal ingredient provides superior insect control at lower levels of the combined active agents than may be achieved when the neuronal sodium channel antagonist or the second insecticidal ingredient is applied alone.
As previously stated, the term neuronal sodium channel antagonist designates a compound which is capable of preventing the ability of a neuron cell to transfer sodium ions across the cell membrane. A neuron cell thus affected is unable to fire, resulting in paralysis, and ultimately mortality, in the target host. Descriptions of neuronal sodium channel antagonists and their mode of action may be found in Pesticide Biochemistry and Physiology, 60: 177-185 or Archives of Insect Biochemistry and Physiology, 37: 91103.
Neuronal sodium channel antagonists include compounds such as those described in U.S. 5,543,573, where hydrazinecarboxamide derivatives are disclosed; U.S. 5,708,170; U.S. 5,324,837 and U.S. 5,462,938, among other publications. The neuronal sodium channel antagonist compounds useful in the composition of this invention are those compounds having the structural formula I <chemistry id="chem0001" num="0001"><img file="EP1198170B1_D0001.tif" /></chemistry> wherein A is CR<sup>4</sup>R<sup>5</sup> or NR<sup>6</sup>; W is O or S; X, Y and Z are each independently H; halogen; OH; CN; NO<sub>2</sub>; C<sub>1</sub>-C<sub>6</sub>-alkyl optionally substituted with one or more halogen, C<sub>1</sub>-C<sub>3</sub>-alkoxy, C<sub>1</sub>-C<sub>3</sub>-haloalkoxy, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyloxy or sulfonyloxy groups; C<sub>1</sub>-C<sub>6</sub>-alkoxy optionally substituted with one or more halogen, C<sub>1</sub>-C<sub>3</sub>-alkoxy or C<sub>3</sub>-C<sub>6</sub>-cycloalkyl groups; C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkylcarbonyloxy, phenyl optionally substituted with one or more halogen, C<sub>1</sub>-C<sub>4-</sub>lkyl, or C<sub>1</sub>-C<sub>4</sub>-alkoxy groups; aminocarbonyloxy optionally substituted with one or more C<sub>1</sub>-C<sub>3</sub>-alkyl groups; C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyloxy; C<sub>1</sub>-C<sub>6</sub>-alkylsulfonyloxy; C<sub>2</sub>-C<sub>6</sub>-alkenyl; or NR<sup>7</sup>R<sup>8</sup>; m, p and q are each independently an integer of 1, 2, 3, 4, or 5; n is an integer of 0, 1 or 2; R, R<sup>1</sup>, R<sup>3</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are each independently H or C<sub>1</sub>-C<sub>4</sub>alkyl; R<sup>6</sup> is H, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>1</sub>-C<sub>6</sub>-haloalkyl, C<sub>1</sub>-C<sub>6</sub>-alkoxyalkyl, C<sub>1</sub>-C<sub>6</sub>-alkoxy, C<sub>1</sub>-C<sub>6</sub>-haloalkoxy, C<sub>2</sub>-C<sub>6</sub>-alkenyl , C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>1</sub>-C<sub>6</sub>-alkylcarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkoxycarbonyl, C<sub>1</sub>-C<sub>6</sub>-alkylthio, or C<sub>1</sub>-C<sub>6</sub>-haloalkylthio; R<sup>7</sup> and R<sup>8</sup> are each independently H or C<sub>1</sub>-C<sub>6</sub>alkyl; and the dotted line configuration C=N represents a double bond or a single bond (i.e. C-N or C=N); or a stereoisomer thereof.
Preferred neuronal sodium channel antagonists suitable for use in the composition of the invention are those compounds of formula I wherein the dotted line configuration C=N represents a double bond.
Particularly preferred neuronal sodium channel antagonists useful in the composition of the invention are those compounds of formula I wherein W is O; X is trifluoromethoxy and is in the 4-position; Y is trifluoromethyl and is in the 3-position; Z is CN and is in the 4-position; A is CH<sub>2</sub>; n is 0; m, p and q are each 1; R and R<sup>1</sup> are each H; and the dotted line configuration C=N represents a double bond; or a stereoisomer thereof.
The second active ingredient of the insecticidal composition of the invention includes one or more compounds selected from Group A: <ul id="ul0002" list-style="none" compact="compact"><li>1) pyrethroid compounds which are known to be insecticidally active such as cypermethrin, cyhalothrin, cyfluthrin, permethrin or the like;</li><li>2) pyrethroid-type compounds which are known to be insecticidally active such as ethofenprox, silafluofen, or the like;</li><li>3) recombinant nucleopolyhedroviruses capable of expressing an insect toxin, preferably an insect neurotoxin such as Androctonus australis insect toxin (AaIT), for example H<sub>z</sub>NPV-AaIT;</li><li>4) organophosphate compounds which are known to be insecticidally active such as profenofos, acephate, sulprofos, malathion, diazinon, methyl parathion, terbufos, or the like;</li><li>5) carbamate compounds which are known to be insecticidally active such as methomyl, thiodicarb, fenothiocarb, or the like;</li><li>6) formamidine compounds which are known to be insecticidally active such as amitraz, chlordimeform, hydramethylnon, chlorfenamidine, or the like;</li><li>7) macrocyclic lactone compounds which are known to be insecticidally active such as spinosad, avermectin, emamectin, milbemectin, nemadectin, moxidectin or the like;</li><li>8) amidinohydrazone compounds which are known to be insecticidally active such as hydramethylnon;</li><li>9) GABA antagonist compounds which are known to be insecticidally effective such as fipronil, endosulfan, or the like;</li><li>10) acetylcholine receptor ligand compounds which are known to be insecticidally effective such as imidacloprid, acetamiprid, nitenpyram, thiamethoxam, or the like.</li></ul>
Descriptions of the above-listed commercially available compounds may be found in The Pesticide Manual, 11th Edition, British Crop Protection Council (1997) among other publications. Descriptions of recombinant nucleopolyhedroviruses capable of expressing an insect toxin include Treacy et al, Proceedings Beltwide Cotton Conference (1999), pp 1076-1083.
Preferred compositions of the invention are those compositions having a neuronal sodium channel antagonist compound of formula I in combination with one or more compounds selected from Group A.
More preferred compositions of the invention are those compositions having a formula I compound wherein W is O; X is trifluoromethoxy and is in the 4-position; Y is trifluoromethyl and is in the 3-position; Z is CN and is in the 4-position; A is CH<sub>2</sub>; n is 0; m, p and q are each independently 1; R and R<sub>1</sub> are each independently H; and the dotted line configuration C=N represents a double bond in combination with one or more compounds selected from Group A.
Each of the compounds of formula I embody assymetric centers which may be represented in the stereoisomeric R-form or S-form. The present invention also includes the R-form, the S-form or mixtures comprising the R-form and the S-form in an arbitrary ratio. Advantageously, the neuronal sodium-channel antagonist compound of formula I may be formulated with a second insecticidally effective ingredient and optionally other customary formulation adjuvants. Said formulation may be dispersed in a solid or liquid diluent for application to the insect, its food supply, breeding ground or habitat as a dilute spray or as a solid dust or dust concentrate.
The active ingredients of the inventive composition may also be formulated separately as a wettable powder, emulsifiable concentrate, aqueous or liquid flowable, suspension concentrate or any one of the conventional formulations used for insect control agents and tank-mixed in the field with water or other inexpensive liquid for application as a liquid spray mixture.
Advantageously, the composition of the invention may be formulated as a bait composition comprising a synergistically effective amount of a combination of a neuronal sodium channel antagonist (I) plus one or more compounds selected from Group A and a solid or liquid edible nutritive substance. A preferred bait composition may contain by weight about 0.01% to 20% active ingredients, preferably a neuronal sodium channel antagonist (I) in combination with hydramethylnon.
In actual practice, the composition of the invention may be applied to the plant foliage or plant stem or to the insect habitat or to the locus of a hygienic pest as a dilute spray prepared from any of the above-said formulations. The ratio of the essential active ingredients of the composition of the invention is about 1 weight part of a neuronal sodium channel antagonist to about 0.01-100 weight parts of one or more compounds selected from Group A.
The compositions of the invention are superior insecticidal compositions and are especially useful for the control of agrohorticultural pests, hygienic pests or wood-eating pests. Said compositions are highly effective for the protection of growing and harvested plants including: leguminous crops such as soybeans, snap beans, peas, wax beans and the like as well as cotton, forage crops, cole crops, leafy vegetables, tobacco, hops, tomatoes, potatoes, flowering ornamentals such as chrysanthemums, vine crops such as grapes, squash, pumpkin or melon and fruit trees such as cherry, peach, apple or citrus, from the ravages of insects.
The insecticidal composition of the invention is found to be highly active against a wide variety of lepidopteran and coleopteran insects such as <i>Helicoverpa zea</i> (cotton bollworm), <i>Heliothis virescens</i> (tobacco budworm), <i>Leptinotarsa</i> decemlineata (Colorado potato beetle), <i>Diabrotica spp.</i> (corn rootworm) and the like.
Beneficially, the composition of the invention may be useful for the prevention and control of hygienic or public health pests such as: Diptera, e.g. houseflies, mosquitoes, or the like; Hymenoptera, e.g. ants, parasitic wasps, wasps or the like;.Blattaria, e.g. cockroaches; or the like.
Further, the compositions of the invention may be particularly useful for the prevention and control of wood-eating insects such as termites (Isoptera), carpenter ants (Hymenoptera), wood-destroying beetles (Coleoptera) or the like.
These and other advantages of the invention may become more apparent from the examples set forth herein below. These examples are provided as illustrations of the invention.
EXAMPLE 1
Evaluation of the Synergistic Insecticidal Effect of a Combination of a Neuronal Sodium Channel Antagonist Plus a Second Insecticide
In this evaluation, <i>Heliothis zea</i> (cotton bollworm), <i>Heliothis virescens</i> (tobacco budworm) and pyrethroid-resistant <i>Heliothis virescens</i> larvae used are obtained from laboratory colonies. Pyrethroid-resistant H. virescens are derived from the PEG-strain [Campannola & Plapp, Proceedings of Beltwide Cotton Conference (1988)].
Cotton leaves are immersed in 1:1 v/v, acetone/water solutions of test compound, or solutions of a combination of test compounds for a period of about 3 seconds. Following immersion, leaves are allowed to air-dry for 2-3 hours. Plastic bioassay trays containing multiple open-faced wells (4.0 x 4.0 x 2.5 cm) are used as the test arenas. Cut portions of a treated leaf, a moistened cotton dental wick and a single third-instar larva are placed into each well, covered with an adhesive vented clear plastic sheet and held under constant fluorescent light at about 27°C for a predetermined period of time. Larval mortality/morbidity is evaluated at 5 days after treatment. All treatments are replicated 4-5 fold in a randomized complete block design with 16-32 larvae per treatment. Using conventional log-probit analysis, the LCso of each treatment is determined.
Using the above protocol, a neuronal sodium channel antagonist (Compound A) may be evaluated alone at dose rates of 0.1 ppm, 1.0 ppm and 10.0 ppm and in combination with 1.0 ppm of a second insecticidal compound. Treatments which may be used are shown in Table I.
As neural sodium channel antagonist the compound of formula Ia (compound A) was used. <chemistry id="chem0002" num="0002"><img file="EP1198170B1_D0002.tif" /></chemistry><tables id="tabl0001" num="0001"><table frame="all"><title>Table I</title><tgroup cols="6" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="26.25mm" /><colspec colnum="2" colname="col2" colwidth="26.25mm" /><colspec colnum="3" colname="col3" colwidth="26.25mm" /><colspec colnum="4" colname="col4" colwidth="26.25mm" /><colspec colnum="5" colname="col5" colwidth="26.25mm" /><colspec colnum="6" colname="col6" colwidth="26.25mm" /><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col1" align="center">Second</entry><entry namest="col2" nameend="col2" align="center">Dose</entry><entry namest="col3" nameend="col3" rowsep="0" /><entry namest="col4" nameend="col6" align="left">Compound A</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="center">Active</entry><entry namest="col2" nameend="col2" align="center">Rate</entry><entry namest="col3" nameend="col3" /><entry namest="col4" nameend="col4" align="center">Dose</entry><entry namest="col5" nameend="col5" align="center">Rate</entry><entry namest="col6" nameend="col6" /></row><row rowsep="1"><entry namest="col1" nameend="col1" align="center">Compound</entry><entry namest="col2" nameend="col2" align="center">(ppm)</entry><entry namest="col3" nameend="col3" align="center">(ppm)</entry><entry namest="col4" nameend="col4" align="center">(ppm)</entry><entry namest="col5" nameend="col5" align="center">(ppm)</entry><entry namest="col6" nameend="col6" align="center">(ppm)</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="center">cypermethrin</entry><entry namest="col2" nameend="col2" align="center">0</entry><entry namest="col3" nameend="col3" align="center">0</entry><entry namest="col4" nameend="col4" align="char" char=".">0.1</entry><entry namest="col5" nameend="col5" align="char" char=".">1.0</entry><entry namest="col6" nameend="col6" align="char" char=".">10.0</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="center">1.0</entry><entry namest="col3" nameend="col3" align="center">0</entry><entry namest="col4" nameend="col4" align="char" char=".">0.1</entry><entry namest="col5" nameend="col5" align="char" char=".">1.0</entry><entry namest="col6" nameend="col6" align="char" char=".">10.0</entry></row><row><entry namest="col1" nameend="col1" align="center">amitraz</entry><entry namest="col2" nameend="col2" align="center">0</entry><entry namest="col3" nameend="col3" align="center">0</entry><entry namest="col4" nameend="col4" align="char" char=".">0.1</entry><entry namest="col5" nameend="col5" align="char" char=".">1.0</entry><entry namest="col6" nameend="col6" align="char" char=".">10.0</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="center">1.0</entry><entry namest="col3" nameend="col3" align="center">0</entry><entry namest="col4" nameend="col4" align="char" char=".">0.1</entry><entry namest="col5" nameend="col5" align="char" char=".">1.0</entry><entry namest="col6" nameend="col6" align="char" char=".">10.0</entry></row><row><entry namest="col1" nameend="col1" align="center">fipronil</entry><entry namest="col2" nameend="col2" align="center">0</entry><entry namest="col3" nameend="col3" align="center">0</entry><entry namest="col4" nameend="col4" align="char" char=".">0.1</entry><entry namest="col5" nameend="col5" align="char" char=".">1.0</entry><entry namest="col6" nameend="col6" align="char" char=".">10.0</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="center">1.0</entry><entry namest="col3" nameend="col3" align="center">0</entry><entry namest="col4" nameend="col4" align="char" char=".">0.1</entry><entry namest="col5" nameend="col5" align="char" char=".">1.0</entry><entry namest="col6" nameend="col6" align="char" char=".">10.0</entry></row><row><entry namest="col1" nameend="col1" align="center">acetamiprid</entry><entry namest="col2" nameend="col2" align="center">0</entry><entry namest="col3" nameend="col3" align="center">0</entry><entry namest="col4" nameend="col4" align="char" char=".">0.1</entry><entry namest="col5" nameend="col5" align="char" char=".">1.0</entry><entry namest="col6" nameend="col6" align="char" char=".">10.0</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="center">1.0</entry><entry namest="col3" nameend="col3" align="center">0</entry><entry namest="col4" nameend="col4" align="char" char=".">0.1</entry><entry namest="col5" nameend="col5" align="char" char=".">1.0</entry><entry namest="col6" nameend="col6" align="char" char=".">10.0</entry></row><row><entry namest="col1" nameend="col1" align="center">spinosad</entry><entry namest="col2" nameend="col2" align="center">0</entry><entry namest="col3" nameend="col3" align="center">0</entry><entry namest="col4" nameend="col4" align="char" char=".">0.1</entry><entry namest="col5" nameend="col5" align="char" char=".">1.0</entry><entry namest="col6" nameend="col6" align="char" char=".">10.0</entry></row><row><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="center">1.0.</entry><entry namest="col3" nameend="col3" align="center">0</entry><entry namest="col4" nameend="col4" align="char" char=".">0.1</entry><entry namest="col5" nameend="col5" align="char" char=".">1.0</entry><entry namest="col6" nameend="col6" align="char" char=".">10.0</entry></row><row><entry namest="col1" nameend="col1" align="center">thiodicarb</entry><entry namest="col2" nameend="col2" align="center">0</entry><entry namest="col3" nameend="col3" align="center">0</entry><entry namest="col4" nameend="col4" align="char" char=".">0.1</entry><entry namest="col5" nameend="col5" align="char" char=".">1.0</entry><entry namest="col6" nameend="col6" align="char" char=".">10.0</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" /><entry namest="col2" nameend="col2" align="center">1.0</entry><entry namest="col3" nameend="col3" align="center">0</entry><entry namest="col4" nameend="col4" align="char" char=".">0.1</entry><entry namest="col5" nameend="col5" align="char" char=".">1.0</entry><entry namest="col6" nameend="col6" align="char" char=".">10.0</entry></row></tbody></tgroup></table></tables>
EXAMPLE 2
Evaluation of the Synergistic Insecticidal Effect Of a Combination Of A Neuronal Sodium Channel Antagonist Plus an Amidinohydrazone
In this evaluation, adult male German cockroaches (Blattella germanica) are used. For each test, a 4.0 g portion of ground Purina Dog Chow (Hi-Pro Glo®) is treated with an acetone solution of test compound alone or in combination with a second test compound. After treatment, the acetone is evaporated and the treated dog chow is placed in a 3/4 oz plastic cup which is placed in a harborage made of folded sheets of blotter paper placed in a plastic box (16" L x 11" W x 6" H) . The plastic box (test arena) is also fitted with a 1 oz narrow mouth bottle with 2 dental wicks inserted at the mouth. A control box is prepared in the same manner using ground dog chow which has been treated with reagent grade acetone. Each treatment is replicated three times. Into each test arena are placed 20 healthy adult male cockroaches which have been reared in an insectary. The test arenas are then stored at 76°F and mortality is determined daily by visual examination. The data obtained are shown in Table II. <tables id="tabl0002" num="0002"><table frame="all"><title>Table II</title><tgroup cols="8" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="19.68mm" /><colspec colnum="2" colname="col2" colwidth="19.68mm" /><colspec colnum="3" colname="col3" colwidth="19.68mm" /><colspec colnum="4" colname="col4" colwidth="19.68mm" /><colspec colnum="5" colname="col5" colwidth="19.68mm" /><colspec colnum="6" colname="col6" colwidth="19.68mm" /><colspec colnum="7" colname="col7" colwidth="19.68mm" /><colspec colnum="8" colname="col8" colwidth="19.68mm" /><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col3" /><entry namest="col4" nameend="col8" align="center">% Mortality</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="center">Test</entry><entry namest="col2" nameend="col2" align="center">% Active</entry><entry namest="col3" nameend="col3" /><entry namest="col4" nameend="col4" align="center">Days</entry><entry namest="col5" nameend="col5" align="center">After</entry><entry namest="col6" nameend="col8" align="center">Treatment</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="center">Compound</entry><entry namest="col2" nameend="col2" align="center">Ingredient</entry><entry namest="col3" nameend="col3" align="center">3</entry><entry namest="col4" nameend="col4" align="center">4</entry><entry namest="col5" nameend="col5" align="center">5</entry><entry namest="col6" nameend="col6" align="center">6 7 8</entry><entry namest="col7" nameend="col7" /><entry namest="col8" nameend="col8" /></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="center">A</entry><entry namest="col2" nameend="col2" align="center">0.05</entry><entry namest="col3" nameend="col3" align="center">0</entry><entry namest="col4" nameend="col4" align="center">0</entry><entry namest="col5" nameend="col5" align="center">0</entry><entry namest="col6" nameend="col6" align="center">0</entry><entry namest="col7" nameend="col7" align="center">0</entry><entry namest="col8" nameend="col8" align="center">0</entry></row><row><entry namest="col1" nameend="col1" align="center">A</entry><entry namest="col2" nameend="col2" align="center">0.10</entry><entry namest="col3" nameend="col3" align="center">1.7</entry><entry namest="col4" nameend="col4" align="center">11.7</entry><entry namest="col5" nameend="col5" align="center">11.7</entry><entry namest="col6" nameend="col6" align="center">11.7</entry><entry namest="col7" nameend="col7" align="center">18.3</entry><entry namest="col8" nameend="col8" align="center">18.3</entry></row><row><entry namest="col1" nameend="col1" align="center">A</entry><entry namest="col2" nameend="col2" align="center">0.50</entry><entry namest="col3" nameend="col3" align="center">5.0</entry><entry namest="col4" nameend="col4" align="center">5.0</entry><entry namest="col5" nameend="col5" align="center">5.0</entry><entry namest="col6" nameend="col6" align="center">5.0</entry><entry namest="col7" nameend="col7" align="center">5.0</entry><entry namest="col8" nameend="col8" align="center">5.0</entry></row><row><entry namest="col1" nameend="col1" align="center">B<sup>1</sup></entry><entry namest="col2" nameend="col2" align="center">1.00</entry><entry namest="col3" nameend="col3" align="center">0</entry><entry namest="col4" nameend="col4" align="center">5.0</entry><entry namest="col5" nameend="col5" align="center">28.3</entry><entry namest="col6" nameend="col6" align="center">71.7</entry><entry namest="col7" nameend="col7" align="center">90.0</entry><entry namest="col8" nameend="col8" align="center">93.3</entry></row><row><entry namest="col1" nameend="col1" align="center">A+B</entry><entry namest="col2" nameend="col2" align="center">0.05+1.0</entry><entry namest="col3" nameend="col3" align="center">0</entry><entry namest="col4" nameend="col4" align="center">20.0</entry><entry namest="col5" nameend="col5" align="center">41.7</entry><entry namest="col6" nameend="col6" align="center">81.7</entry><entry namest="col7" nameend="col7" align="center">95.0</entry><entry namest="col8" nameend="col8" align="center">98.3</entry></row><row><entry namest="col1" nameend="col1" align="center">A+B</entry><entry namest="col2" nameend="col2" align="center">0.10+1.0</entry><entry namest="col3" nameend="col3" align="center">0</entry><entry namest="col4" nameend="col4" align="center">21.7</entry><entry namest="col5" nameend="col5" align="center">51.7</entry><entry namest="col6" nameend="col6" align="center">88.3</entry><entry namest="col7" nameend="col7" align="center">95.0</entry><entry namest="col8" nameend="col8" align="center">95.0</entry></row><row><entry namest="col1" nameend="col1" align="center">A+B</entry><entry namest="col2" nameend="col2" align="center">0.50+1.0</entry><entry namest="col3" nameend="col3" align="center">16.7</entry><entry namest="col4" nameend="col4" align="center">58.3</entry><entry namest="col5" nameend="col5" align="center">80.0</entry><entry namest="col6" nameend="col6" align="center">95.0</entry><entry namest="col7" nameend="col7" align="center">98.3</entry><entry namest="col8" nameend="col8" align="center">100.0</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="center">Control</entry><entry namest="col2" nameend="col2" align="center">0</entry><entry namest="col3" nameend="col3" align="center">0</entry><entry namest="col4" nameend="col4" align="center">1.7</entry><entry namest="col5" nameend="col5" align="center">3.3</entry><entry namest="col6" nameend="col6" align="center">3.3</entry><entry namest="col7" nameend="col7" align="center">3.3</entry><entry namest="col8" nameend="col8" align="center">5.0</entry></row></tbody></tgroup><tgroup cols="8" colsep="0" rowsep="0"><colspec colnum="1" colname="col1" colwidth="19.68mm" /><colspec colnum="2" colname="col2" colwidth="19.68mm" /><colspec colnum="3" colname="col3" colwidth="19.68mm" /><colspec colnum="4" colname="col4" colwidth="19.68mm" /><colspec colnum="5" colname="col5" colwidth="19.68mm" /><colspec colnum="6" colname="col6" colwidth="19.68mm" /><colspec colnum="7" colname="col7" colwidth="19.68mm" /><colspec colnum="8" colname="col8" colwidth="19.68mm" /><tbody valign="top"><row><entry namest="col1" nameend="col8" align="justify"><sup>1</sup>Compound B = hydramethylnon</entry></row></tbody></tgroup></table></tables>
As can be seen from the data shown in Table II, combinations of a neuronal sodium channel antagonist plus an amidinohydrazone insecticide demonstrate synergistic insect control.
EXAMPLE 3
Evaluation of the Synergistic Insecticidal Effect Of a Combination Of A Neuronal Sodium Channel Antagonist Plus A Recombinant Nucleopolvhedrovirus Capable of Expressing An Insect Toxin
In this evaluation, Helicoverpa zea (cotton bollworm) larvae are obtained from a laboratory colony. Test compounds are dissolved in 1:1 v/v acetone/water. Plastic bioassay trays (C-D International, Pitman, NJ) are used as test arenas. Each tray contains 32 openfaced wells, 4.0 x 4.0 x 2.5 cm. A portion (5 ml) of a wheat germ-soybean flour-based artificial diet (Southland Products, Lake village, AR) is poured into each well. After the diet hardened, 0.4 ml of test solution is pipetted onto the diet surface in each well. Test solutions are evenly spread over surfaces of diet by picking up the tray and gently tilting it from side to side. Trays are then held in a vented area for about 2 h, until water is no longer pooled an diet surfaces. A single 4-day-old H. zea larva is then placed an the surface of diet in each well. After larval infestation, each well is covered with an adhesive, vented, clear plastic sheet.
All test arenas are held under constant fluorescent light and a temperature of about 27°C for duration of the assay. Larval mortality is determined at 2, 3, 4 and 7 days after treatment. A larva was considered to be dead if it exhibited little to no movement, even after being shaken in the diet tray. A total of 32 insects were tested for each treatment.
The data obtained are shown in Table III. <tables id="tabl0003" num="0003"><table frame="all"><title>Table III</title><tgroup cols="6" colsep="1" rowsep="0"><colspec colnum="1" colname="col1" colwidth="26.25mm" /><colspec colnum="2" colname="col2" colwidth="26.25mm" /><colspec colnum="3" colname="col3" colwidth="26.25mm" /><colspec colnum="4" colname="col4" colwidth="26.25mm" /><colspec colnum="5" colname="col5" colwidth="26.25mm" /><colspec colnum="6" colname="col6" colwidth="26.25mm" /><thead valign="top"><row rowsep="1"><entry namest="col1" nameend="col3" /><entry namest="col4" nameend="col6" align="center">% Mortality</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="center">Test</entry><entry namest="col2" nameend="col2" align="center">Conc. of % Active</entry><entry namest="col3" nameend="col3" /><entry namest="col4" nameend="col6" align="center">Days After Treatment</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="center">Test Compound</entry><entry namest="col2" nameend="col2" align="center">Ingredient</entry><entry namest="col3" nameend="col3" align="center">2</entry><entry namest="col4" nameend="col4" align="center">3</entry><entry namest="col5" nameend="col5" align="center">4</entry><entry namest="col6" nameend="col6" align="center">7</entry></row></thead><tbody valign="top"><row><entry namest="col1" nameend="col1" align="center">A</entry><entry namest="col2" nameend="col2" align="center">0.1 ppm</entry><entry namest="col3" nameend="col3" align="char" char=".">43.8</entry><entry namest="col4" nameend="col4" align="char" char=".">46.9</entry><entry namest="col5" nameend="col5" align="char" char=".">53.1</entry><entry namest="col6" nameend="col6" align="char" char=".">53.1</entry></row><row><entry namest="col1" nameend="col1" align="center">B<sup>1</sup></entry><entry namest="col2" nameend="col2" align="center">1000 OB<sup>2</sup>/ml</entry><entry namest="col3" nameend="col3" align="char" char=".">0.0</entry><entry namest="col4" nameend="col4" align="char" char=".">9.4</entry><entry namest="col5" nameend="col5" align="char" char=".">18.8</entry><entry namest="col6" nameend="col6" align="char" char=".">40.6</entry></row><row><entry namest="col1" nameend="col1" align="center">B</entry><entry namest="col2" nameend="col2" align="center">500 OB<sup>2</sup>/ml</entry><entry namest="col3" nameend="col3" align="char" char=".">0.0</entry><entry namest="col4" nameend="col4" align="char" char=".">9.4</entry><entry namest="col5" nameend="col5" align="char" char=".">18.8</entry><entry namest="col6" nameend="col6" align="char" char=".">40.6</entry></row><row><entry namest="col1" nameend="col1" align="center">B</entry><entry namest="col2" nameend="col2" align="center">100 OB<sup>2</sup>/ml</entry><entry namest="col3" nameend="col3" align="char" char=".">3.1</entry><entry namest="col4" nameend="col4" align="char" char=".">3.1</entry><entry namest="col5" nameend="col5" align="char" char=".">3.1</entry><entry namest="col6" nameend="col6" align="char" char=".">15.6</entry></row><row><entry namest="col1" nameend="col1" align="center">A+B</entry><entry namest="col2" nameend="col2" align="center">0.1+1000</entry><entry namest="col3" nameend="col3" align="char" char=".">87.5</entry><entry namest="col4" nameend="col4" align="char" char=".">90.6</entry><entry namest="col5" nameend="col5" align="char" char=".">93.8</entry><entry namest="col6" nameend="col6" align="char" char=".">96.9</entry></row><row><entry namest="col1" nameend="col1" align="center">A+B</entry><entry namest="col2" nameend="col2" align="center">0.1+500</entry><entry namest="col3" nameend="col3" align="char" char=".">75.0</entry><entry namest="col4" nameend="col4" align="char" char=".">78.1</entry><entry namest="col5" nameend="col5" align="char" char=".">84.4</entry><entry namest="col6" nameend="col6" align="char" char=".">87.5</entry></row><row><entry namest="col1" nameend="col1" align="center">A+B</entry><entry namest="col2" nameend="col2" align="center">0.1+100</entry><entry namest="col3" nameend="col3" align="char" char=".">62.5</entry><entry namest="col4" nameend="col4" align="char" char=".">75.0</entry><entry namest="col5" nameend="col5" align="char" char=".">75.0</entry><entry namest="col6" nameend="col6" align="char" char=".">78.1</entry></row><row rowsep="1"><entry namest="col1" nameend="col1" align="center">Control</entry><entry namest="col2" nameend="col2" align="center">0</entry><entry namest="col3" nameend="col3" align="char" char=".">3.1</entry><entry namest="col4" nameend="col4" align="char" char=".">3.1</entry><entry namest="col5" nameend="col5" align="char" char=".">3.1</entry><entry namest="col6" nameend="col6" align="char" char=".">3.1</entry></row></tbody></tgroup><tgroup cols="6" colsep="0" rowsep="0"><colspec colnum="1" colname="col1" colwidth="26.25mm" /><colspec colnum="2" colname="col2" colwidth="26.25mm" /><colspec colnum="3" colname="col3" colwidth="26.25mm" /><colspec colnum="4" colname="col4" colwidth="26.25mm" /><colspec colnum="5" colname="col5" colwidth="26.25mm" /><colspec colnum="6" colname="col6" colwidth="26.25mm" /><tbody valign="top"><row><entry namest="col1" nameend="col6" align="justify"><sup>1</sup>Compound B = HzNPV-AaIT, <i>Helicoverpa zea</i> Nucleopolyhedrovirus which expresses <i>Androctonus australis</i> insect toxin</entry></row><row><entry namest="col1" nameend="col6" align="justify"><sup>2</sup>OB = viral occlusion bodies</entry></row></tbody></tgroup></table></tables>
As can be seen from the data shown in Table III, combinations of a neuronal sodium channel antagonist plus a recombinant nucleopolyhedrovirus which is capable of expressing an insect toxin demonstrate synergistic insect control.
Contents6
11 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11
Every citation, both ways
| Document | Relation | Office | Cited during |
|---|---|---|---|
| US8916613B2 | Cited by | United States of America | Applicant |
| US2014243326A1 | Cited by | United States of America | Pre-grant |
66 members in 26 offices
Priority claims14
| Document | Office | Kind | Date |
|---|---|---|---|
| 124306P | United States of America | – | |
| 12430699 | United States of America | P | |
| 12430699 | United States of America | P | |
| 158201P | United States of America | – | |
| 15820199 | United States of America | P | |
| 15820199 | United States of America | P | |
| 0005879 | United States of America | W | |
| 0005879 | United States of America | W | |
| 124306P | – | – | – |
| 158201P | – | – | – |
| US19990124306P | – | – | – |
| US19990158201P | – | – | – |
| US2000005879 | – | – | – |
| WO2000US05879 | – | – | – |
Members66
| Document | Office | Kind | |
|---|---|---|---|
| CA2367984A1 | Canada | A1 | |
| WO0054591A2 | World Intellectual Property Organization (WIPO) | A2 | |
| AU3617500A | Australia | A | |
| WO0054591A3 | World Intellectual Property Organization (WIPO) | A3 | |
| BR0008930A | Brazil | A | |
| KR20020021370A | Republic of Korea | A | |
| EP1198170A2 | European Patent Office (EPO) | A2 | |
| EA200100923A1 | Eurasian Patent Organization (EAPO) | A1 | |
| CN1351469A | China | A | |
| IL145255D0 | Israel | D0 | |
| HU0200278A2 | Hungary | A2 | |
| CZ20013298A3 | Czechia | A3 | |
| AR022900A1 | Argentina | A1 | |
| SK12612001A3 | Slovakia | A3 | |
| US6479543B1 | United States of America | B1 | |
| US2002177597A1 | United States of America | A1 | |
| ZA200107484B | South Africa | B | |
| HU0200278A3 | Hungary | A3 | |
| NZ514000A | New Zealand | A | |
| PL351551A1 | Poland | A1 | |
| JP2003517455A | Japan | A | |
| AU765767B2 | Australia | B2 | |
| MXPA01009191A | Mexico | A | |
| UA71953C2 | Ukraine | C2 | |
| EP1198170B1This record | European Patent Office (EPO) | B1 | |
| AT312511T | Austria | T | |
| DE60024826D1 | Germany | D1 | |
| DK1198170T3 | Denmark | T3 | |
| ES2250117T3 | Spain | T3 | |
| TWI256289B | Taiwan Province of China | B | |
| DE60024826T2 | Germany | T2 | |
| CN1799358A | China | A | |
| CN1279822C | China | C | |
| EA007716B1 | Eurasian Patent Organization (EAPO) | B1 | |
| IL145255A | Israel | A | |
| KR100696328B1 | Republic of Korea | B1 | |
| MY133289A | Malaysia | A | |
| US2008108639A1 | United States of America | A1 | |
| US2008125420A1 | United States of America | A1 | |
| US2008125421A1 | United States of America | A1 | |
| US2008132470A1 | United States of America | A1 | |
| US2008132498A1 | United States of America | A1 | |
| US2008139542A1 | United States of America | A1 | |
| US2008139543A1 | United States of America | A1 | |
| US2008139643A1 | United States of America | A1 | |
| US2008139658A1 | United States of America | A1 | |
| CN101218919A | China | A | |
| PL199694B1 | Poland | B1 | |
| SK286647B6 | Slovakia | B6 | |
| CA2367984C | Canada | C | |
| US7772281B2 | United States of America | B2 | |
| US7772282B2 | United States of America | B2 | |
| US7772283B2 | United States of America | B2 | |
| US7838559B2 | United States of America | B2 | |
| US7842728B2 | United States of America | B2 | |
| CN101218919B | China | B | |
| BR0008930B1 | Brazil | B1 | |
| AR081807A2 | Argentina | A2 | |
| BR0017605B1 | Brazil | B1 | |
| US8362074B2 | United States of America | B2 | |
| BR0017604B1 | Brazil | B1 | |
| BR0017616B1 | Brazil | B1 | |
| BR0017614B1 | Brazil | B1 | |
| BR0017617B1 | Brazil | B1 | |
| BR0017618B1 | Brazil | B1 | |
| CZ303846B6 | Czechia | B6 |
71 legal events, as 13 offices reported them to INPADOC
Over the term
Point at a mark for the eventEvents
| Event | Code | Office | |
|---|---|---|---|
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Announcement of lapse in spainLapsedFD2A | FD2A | ES | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Notification of lapseLapsedST | ST | FR | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapse due to non-payment of feesLapsedML | ML | GR | |
| Lapsed because of non-payment of the annual feeLapsedMM | MM | NL | |
| Gb: european patent ceased through non-payment of renewal feeCeasedGBPC | GBPC | EP | |
| Lapse because of not paying annual feesLapsedMM01 | MM01 | AT | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Patent ceasedCeasedPL | PL | CH | |
| Ep patent lapsedLapsedEBP | EBP | DK | |
| Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal feeWithdrawnR119 | R119 | DE | |
| Annulment/lapse due to non-payment of fees, searched and examined patentLapsedLAPSE DUE TO NON-PAYMENT OF FEESMM4A | MM4A | PT | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Patent lapsedLapsedMM4A | MM4A | IE | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Ep patent has lapsedLapsedEUG | EUG | SE | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Annual fee paid to national office [announced via postgrant information from national office to epo]GrantedPGFP | PGFP | EP | |
| Change of the address of the representativeSCHMAUDER & PARTNER AG PATENT- UND MARKENANWAELTE VSP;ZWAENGIWEG 7;8038 ZUERICH (CH)PCAR | PCAR | CH | |
| No opposition filedOpposition26N | 26N | EP | |
| No opposition filed within time limitOppositionORIGINAL CODE: 0009261PLBE | PLBE | EP | |
| Information on the status of an ep patent application or granted ep patentGrantedSTATUS: NO OPPOSITION FILED WITHIN TIME LIMITSTAA | STAA | EP | |
| Fr: translation filedET | ET | EP | |
| Definitive protectionFG2A | FG2A | ES | |
| Lapsed in a contracting state [announced via postgrant information from national office to epo]LapsedPG25 | PG25 | EP | |
| Translation of granted ep patentGrantedTRGR | TRGR | SE | |
| Ep patent with danish claimsT3 | T3 | DK | |
| Ep patent validated in greeceEP | EP | GR | |
| Corresponds to:REF | REF | EP | |
| European patents granted designating irelandGrantedFG4D | FG4D | IE | |
| European patent takes effect as a national patent in ch/liEP | EP | CH | |
| New agentNV | NV | CH | |
| Designated contracting statesAK | AK | EP | |
| European patent grantedGrantedFG4D | FG4D | GB | |
| (expected) grantORIGINAL CODE: 0009210GRAA | GRAA | EP | |
| Grant fee paidORIGINAL CODE: EPIDOSNIGR3GRAS | GRAS | EP | |
| Despatch of communication of intention to grant a patentORIGINAL CODE: EPIDOSNIGR1GRAP | GRAP | EP | |
| First examination report despatched17Q | 17Q | EP | |
| Request for examination filed17P | 17P | EP | |
| Designated contracting statesAK | AK | EP | |
| Request for extension of the european patentAL;LT;LV;MK;RO;SIAX | AX | EP | |
| Public reference made under article 153(3) epc to a published international application that has entered the european phaseORIGINAL CODE: 0009012PUAI | PUAI | EP |
Numbers
- Publication
- 1198170
- Publication, DOCDB
- 1198170
- Publication, EPODOC
- EP1198170
- Application
- 914839
- Application, DOCDB
- 00914839
- Application, EPODOC
- EP20000914839
Titles3
- German
- SYNERGISTISCHE INSEKTIZIDE ZUSAMMENSETZUNGEN
- English
- SYNERGISTIC INSECTICIDAL COMPOSITIONS
- French
- COMPOSITIONS INSECTICIDES SYNERGIQUES
Classification
- CPC, 7
- A01N47/34
- A01N37/50
- A01N43/56
- A01N47/38
- A01N63/50
- Y02A50/30
- A01N2300/00
- IPC, 11
- A01N37 52
- A01N43 16
- A01N43 40
- A01N43 54
- C07C281 14
- A01N43 56
- A01N43 58
- A01N47 24
- A01N47 34
- A01N47 40
- A01N53 08
Designated states19
- Contracting states, 19
- Austria
- Belgium
- Switzerland
- Cyprus
- Germany
- Denmark
- Spain
- Finland
- France
- United Kingdom
- Greece
- Ireland
- Italy
- Liechtenstein
- Luxembourg
- Monaco
- Netherlands (Kingdom of the)
- Portugal
- Sweden
